Migraine and Hormonal Contraceptives: Risks, Benefits, and What to Discuss With Your Doctor

The choice of contraceptive method is an important clinical consideration for women with migraine, particularly migraine with aura. Hormonal contraceptives influence estrogen levels, and estrogen plays a central role in migraine susceptibility. Depending on the type of contraceptive, the dose, and the delivery method, hormonal contraceptives can worsen migraine, improve it, or have variable effects that require individualized assessment and monitoring.

This is an area where clinical guidance has evolved significantly over the past two decades, and where the conversation between a woman with migraine and her healthcare provider needs to be specific and informed by her individual migraine pattern, cardiovascular risk profile, and contraceptive needs.

Combined Oral Contraceptives and Migraine With Aura

Current clinical guidelines from major headache and neurology organizations advise against the use of combined oral contraceptives, which contain both estrogen and progestogen, in women with migraine with aura. This guidance reflects the additive stroke risk associated with the combination of migraine with aura, exogenous estrogen, and the prothrombotic effects of combined oral contraceptives.

The World Health Organization medical eligibility criteria for contraceptive use classify combined oral contraceptives as category 4, meaning unacceptable health risk, for women with migraine with aura. This is one of the strongest contraindications in the eligibility criteria and reflects the substantial elevation in stroke risk associated with this combination, particularly in women who also smoke or have other cardiovascular risk factors.

Combined Oral Contraceptives and Migraine Without Aura

The guidance is less restrictive for women with migraine without aura. Combined oral contraceptives are not absolutely contraindicated in this population, but they require careful consideration because they can worsen migraine frequency and severity in some women through the estrogen withdrawal that occurs during the pill-free interval.

The estrogen withdrawal during the pill-free days of a standard combined oral contraceptive cycle produces a drop in estrogen levels similar to the perimenstrual estrogen withdrawal that drives menstrual migraine. Women who experience worsening migraine during the pill-free interval may benefit from alternative regimens that reduce or eliminate the hormone-free interval, such as extended-cycle or continuous use regimens that minimize estrogen fluctuation.

Progestogen-Only Contraceptives

Progestogen-only contraceptives, including the progestogen-only pill, hormonal intrauterine devices, subdermal implants, and depot injections, are generally considered appropriate for women with migraine, including migraine with aura. They do not contain estrogen and do not carry the estrogen-associated stroke risk that makes combined oral contraceptives problematic in women with migraine with aura.

The effect of progestogen-only contraceptives on migraine frequency varies between individuals and between different progestogen formulations. Some women experience improvement in migraine with progestogen-only methods, while others experience no change or worsening. Individual monitoring after initiating any hormonal contraceptive is appropriate.

Non-Hormonal Contraceptive Options

For women with migraine with aura who prefer to avoid hormonal methods entirely, non-hormonal options including copper intrauterine devices and barrier methods provide effective contraception without influencing the hormonal environment relevant to migraine. Copper intrauterine devices in particular offer highly effective long-term contraception without hormonal effects, making them a suitable option for women with migraine with aura who want to avoid any hormonal influence on their migraine pattern.

What to Discuss With a Healthcare Provider

Women with migraine who are considering contraception should discuss their specific migraine diagnosis, including whether they experience aura, with their healthcare provider before selecting a method. This conversation should include the current migraine pattern, cardiovascular risk factors including smoking history and blood pressure, and contraceptive preferences and priorities.

A provider who is not aware of the migraine with aura diagnosis may prescribe combined oral contraceptives without recognizing the contraindication. Women with migraine with aura who are offered combined oral contraceptives should ensure that their provider is aware of the aura and has considered the clinical guidance before proceeding. Any change in migraine pattern following initiation of a hormonal contraceptive warrants prompt discussion with the prescribing provider.